Biophytis (EPA:ALBPS) | Finanzwire

Basculer en Français

10605	Companies
225020	Keywords
153742	Articles
119080	Press releases

Home
Companies
Biophytis

BRIEF

published on 06/10/2024 at 08:21, 2 years ago

Biophytis files IND application for phase 2 study in obesity

FDA Biophytis Phase 2 BIO101 Obesity
REGULATED PRESS RELEASE

published on 06/10/2024 at 08:18, 2 years ago

Biophytis announces filing of an IND application with the US FDA for its phase 2 study in obesity
Biophytis files IND application with US FDA for phase 2 obesity study with BIO101 (20-hydroxyecdysone) to assess muscle strength improvement in lower limbs and secondary endpoints like mobility and body composition

FDA Biophytis BIO101 IND Application Obesity Study
PRESS RELEASE

published on 06/10/2024 at 08:16, 2 years ago

Biophytis announces filing of an IND application with the US FDA for its phase 2 study in obesity
Biophytis submits IND application to US FDA for phase 2 obesity study with BIO101 (20-hydroxyecdysone). Study to assess muscle strength & body composition. Research led by Professor Marc-André Cornier

Biophytis BIO101 IND Application Obesity Study Professor Marc-André Cornier
BRIEF

published on 06/07/2024 at 08:28, 2 years ago

Biophytis Announces Combined General Meeting on June 24, 2024

Shareholders Biophytis General Meeting Voting Agenda
REGULATED PRESS RELEASE

published on 06/07/2024 at 08:23, 2 years ago

Combined General Meeting of June 24, 2024
Biophytis SA to hold Combined General Meeting (CGM) on June 24, 2024 in Paris. Shareholders encouraged to vote in advance via multiple methods. Details available on the company's website

Shareholders Voting Combined General Meeting Biophytis SA CGM
BRIEF

published on 06/07/2024 at 07:44, 2 years ago

Biophytis Combined General Meeting scheduled for June 24, 2024

Shareholders Biophytis Paris General Assembly Vote
PRESS RELEASE

published on 06/07/2024 at 07:39, 2 years ago

Combined General Meeting of June 24, 2024
Biophytis to hold Combined General Meeting (CGM) on June 24, 2024 at Sorbonne Université. Shareholders urged to vote in advance. Company specializes in age-related disease therapeutics

Shareholders Biophytis Therapeutics Combined General Meeting Age-related Diseases
BRIEF

published on 05/14/2024 at 07:05, 2 years 1 month ago

Biophytis Unveils Phase 2 OBA Clinical Study Design in Obesity

Biophytis Obesity Treatment Clinical Trial BIO101 OBA Clinical Study
PRESS RELEASE

published on 05/14/2024 at 07:00, 2 years 1 month ago

Biophytis announces the design of its phase 2 OBA clinical study in obesity
Biophytis announces the design of its phase 2 OBA clinical study in obesity with BIO101 (20-hydroxyecdysone), targeting muscle preservation in patients with obesity undergoing weight loss treatment with GLP-1 RAs

Biophytis BIO101 Muscle Preservation Obesity Phase 2 OBA Clinical Study
REGULATED PRESS RELEASE

published on 05/14/2024 at 07:00, 2 years 1 month ago

Biophytis announces the design of its phase 2 OBA clinical study in obesity
Biophytis announces the design of its phase 2 OBA clinical study in obesity with BIO101 (20-hydroxyecdysone), aiming to test efficacy and safety for muscle function in obese patients. Study to start mid-2024 with results expected in 2025

Biophytis BIO101 Obesity Phase 2 OBA Clinical Study Muscle Function

Accesswire

Published on 06/22/2026 at 03:00, 4 hours 20 minutes ago

Tunkillia Pre-Feasibility Study Begins
Published on 06/20/2026 at 01:00, 2 days 6 hours ago

Onco-Innovations Announces Non-Brokered LIFE Offering
Published on 06/20/2026 at 00:00, 2 days 7 hours ago

Onco-Innovations Reports Completion of 300g Active Pharmaceutical Ingredient for ONC010 Scale-Up Supporting IND-Enabling Development
Published on 06/19/2026 at 04:30, 3 days 2 hours ago

Uraniumx Discovery Corp. Announces Acquisition of Common Shares of Gold'n Futures Mineral Corp
Published on 06/19/2026 at 01:20, 3 days 6 hours ago

American Hotel Income Properties REIT LP Reports Voting Results of Annual and Special Meeting

View all ACCESSWIRE

EQS Group

Published on 06/22/2026 at 07:00, 20 minutes ago

Sandoz to host capital markets day: maximising Sandoz value in its golden decade for biosimilars
Published on 06/22/2026 at 06:05, 1 hour 14 minutes ago

adidas and GLO Brands B.V., debuts ADIDAS PRO WORK, a new safety footwear range, combining performance, protection and style for the modern worksite
Published on 06/22/2026 at 04:05, 3 hours 14 minutes ago

Optro Accelerates Global Growth with Singapore Hub, Delivering Agentic GRC to APAC Enterprises
Published on 06/20/2026 at 21:25, 1 day 9 hours ago

VIVATECH 2026 CELEBRATES ITS 10TH ANNIVERSARY WITH A RECORD EDITION SURPASSING 200,000 VISITORS
Published on 06/20/2026 at 06:00, 2 days 1 hour ago

Successful debut of International Symposium on Emergency Response and Aeromedical Services in Hong Kong

Les Echos

Published on 06/19/2026 at 19:33, 2 days 11 hours ago

Disclosure of transactions in own shares from June 15 to June 19, 2026
Published on 06/19/2026 at 19:23, 2 days 11 hours ago

Imerys-06-2026-information-share-capital-and-voting-rights-as-of-31-May-2026
Published on 06/18/2026 at 18:00, 3 days 13 hours ago

Outstanding shares and voting rights statement at 31 May 2026
Published on 06/18/2026 at 17:45, 3 days 13 hours ago

EURAZEO INVESTS IN LAURALU, A PAN-EUROPEAN PROVIDER OF DEPLOYABLE INDUSTRIAL INFRASTRUCTURE
Published on 06/18/2026 at 17:38, 3 days 13 hours ago

Statement of transactions in own shares from June 8, 2026 to June 12, 2026

View all LES ECHOS COMFI WIRE